Sunitinib-induced complete response in metastatic renal cancer expressing neuroendocrine markers: A new predictive factor? - Abstract

BACKGROUND: To date, no predictive factors are recognized and applied in the therapeutic choice for metastatic renal cell carcinoma.

Due to significant side-effects and costs, which are relevant issues in this setting, optimization of treatments has become a priority.

CASE REPORT: We herein report a case of complete remission of metastatic renal cell carcinoma after 1 year of treatment with sunitinib. Since pancreatic metastases were detected by a 68Ga-DOTA-NOC positron emission tomography, it was decided to perform a histological revision of the specimens, with immunohistochemical staining for neuroendocrine markers on the primary tumor.

CONCLUSION: On the basis of the detection of neuroendocrine markers on the primary neoplasm, together with pancreatic metastases positive on a 68Ga-DOTA-NOC positron emission tomography (PET), we hypothesize and discuss about a potential role of specific neuroendocrine markers as predictive indicators of response to sunitinib (and allegedly to other target therapies) in the treatment of this neoplasm.

Written by:
Gambini D, Locatelli E, Gianelli U, Bareggi C, Galassi B, Visintin R, Massironi S, Dell'orto PG, Tomirotti M.   Are you the author?
Unit of Medical Oncology, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy; Hematopathology Section, Pathology Unit, Department of Pathophysiology and Transplantation, University of Milan School of Medicine, Milan, Italy; Unit of Gastroenterology and Endoscopy, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy; Urology Unit, Clinical Surgery I, University Milan School of Medicine, IRCCS Ca' Granda - Maggiore Policlinico Hospital Foundation, Milan, Italy.

Reference: Anticancer Res. 2014 Dec;34(12):7361-5.


PubMed Abstract
PMID: 25503173

UroToday.com Renal Cancer Section